BR0313204A - Métodos para tratamento e prevenção de condições gastrointestinais - Google Patents

Métodos para tratamento e prevenção de condições gastrointestinais

Info

Publication number
BR0313204A
BR0313204A BR0313204-8A BR0313204A BR0313204A BR 0313204 A BR0313204 A BR 0313204A BR 0313204 A BR0313204 A BR 0313204A BR 0313204 A BR0313204 A BR 0313204A
Authority
BR
Brazil
Prior art keywords
methods
prevention
treatment
nitric oxide
conditions
Prior art date
Application number
BR0313204-8A
Other languages
English (en)
Inventor
Pamela T Manning
Jane R Connor
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0313204A publication Critical patent/BR0313204A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"MéTODOS PARA TRATAMENTO E PREVENçãO DE CONDIçõES GASTROINTESTINAIS". A presente invenção refere-se a métodos terapêuticos para a prevenção e tratamento de condições e doenças do trato gastrointestinal envolvendo uma sobre-produção de óxido nítrico pela sintase óxido nítrico induzível, incluindo os métodos a administração a um indivíduo, em necessidade de tal, de uma quantidade terapeuticamente eficaz de um inibidor seletivo da sintase óxido nítrico induzível (iNOS). Os métodos também incluem a utilização de inibidores seletivos de INOS em combinação com outros agentes terapêuticos, incluindo agentes antimicrobianos e agentes antisecretórios.
BR0313204-8A 2002-08-02 2003-07-25 Métodos para tratamento e prevenção de condições gastrointestinais BR0313204A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40066002P 2002-08-02 2002-08-02
PCT/US2003/023324 WO2004012726A2 (en) 2002-08-02 2003-07-25 Methods for treatment and prevention of gastrointestinal conditions

Publications (1)

Publication Number Publication Date
BR0313204A true BR0313204A (pt) 2005-06-28

Family

ID=31495851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313204-8A BR0313204A (pt) 2002-08-02 2003-07-25 Métodos para tratamento e prevenção de condições gastrointestinais

Country Status (13)

Country Link
US (1) US20040127569A1 (pt)
EP (1) EP1528921A2 (pt)
JP (1) JP2006500342A (pt)
KR (1) KR20050059051A (pt)
CN (1) CN1674885A (pt)
AU (1) AU2003256810A1 (pt)
BR (1) BR0313204A (pt)
CA (1) CA2494284A1 (pt)
IL (1) IL166083A0 (pt)
MX (1) MXPA05001255A (pt)
PL (1) PL375375A1 (pt)
TW (1) TW200412940A (pt)
WO (1) WO2004012726A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207188B2 (en) * 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668651A (en) * 1985-09-05 1987-05-26 Union Carbide Corporation Transition metal complex catalyzed processes
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DK0751930T3 (da) * 1994-03-24 2000-04-17 Searle & Co Amidinoderivater anvendelige som nitrogenoxid-synthase-inhibitorer
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US5830917A (en) * 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
DE19541146A1 (de) * 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) * 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE69836422T2 (de) * 1997-02-19 2007-06-14 Berlex, Inc., Richmond N-heterocyclische derivate als nos inhibitoren
GB9811599D0 (en) * 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
PT1265860E (pt) * 2000-03-24 2005-10-31 Pharmacia Corp Compostos amidino uteis como inibidores de sintase de oxido nitrico
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR030416A1 (es) * 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US6586747B1 (en) * 2000-06-23 2003-07-01 Ebco Industries, Ltd. Particle accelerator assembly with liquid-target holder
CA2410391A1 (en) * 2000-06-28 2002-11-28 Ssp Co., Ltd. Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR030741A1 (es) * 2000-09-15 2003-09-03 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa

Also Published As

Publication number Publication date
CA2494284A1 (en) 2004-02-12
WO2004012726A3 (en) 2004-06-03
KR20050059051A (ko) 2005-06-17
JP2006500342A (ja) 2006-01-05
AU2003256810A1 (en) 2004-02-23
PL375375A1 (en) 2005-11-28
IL166083A0 (en) 2006-01-15
WO2004012726A2 (en) 2004-02-12
CN1674885A (zh) 2005-09-28
US20040127569A1 (en) 2004-07-01
TW200412940A (en) 2004-08-01
EP1528921A2 (en) 2005-05-11
MXPA05001255A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BR0013478A (pt) Combinação sinergìstica
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
WO2005046657A3 (en) Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
CA2632207C (en) Use of calcitonin for the treatment of ra
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
IS7898A (is) Ný samverkandi samsetning sem felur í sér róflúmílast og formóteról
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
BR0313204A (pt) Métodos para tratamento e prevenção de condições gastrointestinais
EP1626731A4 (en) ANTI-INFLAMMATORY MEDICINE PREPARATIONS FOR INFLAMMATORY INFLAMMATION AND THE THERAPY OR PROPHYLAXIS OF GASTRIC TOXICITY
IS7899A (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
WO2003097163A3 (en) Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
BR0309808A (pt) Combinação para o tratamento de distúrbios das vias aéreas
BR0212991A (pt) Métodos de tratamento oftalmológico utilizando inibidores seletivos de inos
BR9612245A (pt) Inibidor de óxido nitrico (no) sintase para tratamento ou prevenção de diabetes tipo ii
BRPI0407574A (pt) combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda
WO2003066806A3 (en) Therapeutic use of aziridino compounds
WO2003077831A3 (en) Compositions and methods for treating mdma-induced toxicity

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]